Ocuphire Pharma Results Presentation Deck

RM 11 Primary Endpoint: % of Subjects Study Eye Returning to Baseline PD at 90 Min Nyxol Met the Primary Endpoint at 90 Min; Additionally at 60 Min and All Subsequent Timepoints Percent of Subjects (%) 100% 80% 60% 40% 20% 0% 3% Placebo n=91 1% 0.5 2% MIRA-2 Phase 3 Trial Study Eye (mITT Population) Percent of Subjects Returning to ≤ 0.2 mm of Baseline Nyxol n=94 p<0.0001 28% 1 p<0.0001 49% 7% p<0.0001 59% 11% p<0.0001 80% 2 18% 1.5 Time Post-Treatment with Nyxol/Placebo (Hours) 3 Source: MIRA-2 TLR table #14.2.1.1 (mITT). Data include all three mydriatics (Phenylephrine, Tropicamide, Paremyd) p<0.0001 82% 30% 4 p<0.0001 90% 45% 6 Ocuphire PHARMA

View entire presentation